Additionally, the clinical evolution of T2DM over the five years (OR 0.022; 95%CI: 0.001–0.846; p = 0.004) and the pre-surgery insulin treatment—in monotherapy (OR: 0.001; 95%CI: 0.001–0.158; p = 0.009) or in combination with other anti-hyperglycemic drugs (OR: 0.001; 95%CI: 0.001–0.125; p = 0.014)—were associated with lower odds of T2DM remission (Table 6). Here, INS is linked to type 2 diabetes mellitus.